Michael E Steuer, MD, PC
Michael E Steuer, MD, PC was paid $2.63M by Medicaid between Jan 2018 and Dec 2024, across 34 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 23% of everything it billed.
33Billing provider infoMICHAEL E STEUER, MD, PC
CORDOVA, TN 38018
CORDOVA, TN 38018
33aNPI1861824559assigned 08/05/2013
33bProvider typeSpecialist
28Total paid$2.63M
24GClaims143,521
24DCodes billed34
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in Tennessee
Rank by total paid#11 of 252
Median peer was paid$57K
This provider vs. median46×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,373 | $234K | |
| 2019 | 27,208 | $484K | |
| 2020 | 25,739 | $556K | |
| 2021 | 23,724 | $488K | |
| 2022 | 16,324 | $266K | |
| 2023 | 21,424 | $352K | |
| 2024incomplete | 15,729 | $251K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 34,887 | 29,216 | $603K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 20,978 | 16,263 | $490K |
| 64483 | 7.2% | 4,523 | 3,928 | $188K | |
| 64493 | 6.1% | 6,634 | 4,134 | $161K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.1% | 21,898 | 16,081 | $161K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.7% | 2,939 | 2,269 | $150K |
| 27096 | 5.2% | 1,793 | 1,636 | $137K | |
| 64635 | 3.7% | 1,119 | 845 | $96K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.1% | 10,988 | 8,330 | $82K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.9% | 4,262 | 2,868 | $77K |
| 64494 | 2.5% | 6,589 | 4,108 | $65K | |
| 99152 | 2.5% | 6,089 | 4,468 | $65K |
22 more codes
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.2% | 3,571 | $58K |
| 64636 | 2.1% | 1,675 | $56K | |
| 64484 | 1.7% | 3,387 | $44K | |
| 64495 | 1.6% | 4,637 | $42K | |
| 64454 | 1.4% | 879 | $38K | |
| 99203 | Doctor's office visit, new patient (routine) | 1.3% | 1,133 | $33K |
| 64479 | <1% | 393 | $18K | |
| 64418 | <1% | 553 | $17K | |
| 64490 | <1% | 445 | $12K | |
| 64450 | <1% | 303 | $9K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | <1% | 21 | $6K |
| 77002 | <1% | 1,015 | $5K | |
| 64491 | <1% | 387 | $4K | |
| 20610 | <1% | 188 | $4K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,259 | $2K |
| 64492 | <1% | 206 | $2K | |
| 64480 | <1% | 105 | $1K | |
| 64999 | <1% | 25 | $1K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 534 | $1K |
| 64625 | <1% | 20 | $665.84 | |
| 20611 | <1% | 13 | $482.21 | |
| 80305 | <1% | 73 | $56.31 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTEUER, MICHAEL (MD/OWNER/PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Midsouth Interventional Pain Institute, LLC | Germantown, TN | $2.08M |
| Michael E Steuer MD PC | Jackson, TN | $1.02M |
| Midsouth Interventional Pain Institute, LLC | Southaven, MS | $742K |
| Michael E Steuer MD PC | Southaven, MS | $637K |
| Michael E Steuer MD PC | Tupelo, MS | $266K |
| Midsouth Interventional Pain Institute, LLC | Jackson, TN | $252K |
| Michael E. Steuer MD PC | Oxford, MS | $234K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.